

To whom it may concern

Date: November 11th, 2025

Company name: StemCell Institute Inc.

Representative: Takafumi Shimizu; President and CEO

November 17: “World Cord Blood Day”

Japan’s leading private cord blood bank with a 99% domestic share — StemCell Institute —
introduces its state-of-the-art facilities and expansion into Southeast Asia

~ Nationwide coverage with processing started within 48 hours, and a robust storage system with zero accidents
since establishment ~

Monday, November 17, 2025, is ‘World Cord Blood Day’. ※1

This day is an international awareness day established by the U.S.-based nonprofit organization Save the Cord Foundation, which promotes the importance of cord blood—a valuable medical resource—throughout the world, including both public and private banks.

StemCell Institute Inc. (Head Office: Minato-ku, Tokyo; President and CEO: Takafumi Shimizu; hereinafter “the Company”) supports this philosophy and, under a reliable quality management system certified by Japan’s Ministry of Health, Labour and Welfare for the manufacture of specified cell products and accredited by the international organization AABB, has been supporting families’ futures as a private cord and cord blood bank for over 25 years.

※1 In 2025, the date has been exceptionally set to the 17th.

Cord blood banking for babies and their families — expanding across more than 90 countries worldwide

Private cord blood banks are operating in more than 90 countries worldwide※2, and storing cord blood for newborn babies and their families has now become a common choice. As a key player supporting the quality standards in Japan, our company has established a system that meets international standards in every aspect — from transportation and processing to storage.

※2 Parent's Guide to Cord Blood HP "Family banking"

Cell Transportation: Ensuring reliable delivery from anywhere in Japan

We have established a system that ensures safely and reliably delivering collected cord blood from anywhere in Japan to our cell processing center and starting processing within 48 hours (according to our in-house standards).

The specially designed transport boxes, created to maintain the proper temperature, protect the cells from impact and temperature fluctuations while recording all temperature data during transit. In addition, the optimal delivery route is selected based on weather and traffic conditions, as we carefully fulfill our responsibility to safeguard and carry the “potential of life” into the future.




Specially designed transport box

Cell Processing: Medical-Grade Quality Control Based on International Standards

Our cell processing center has obtained the “Specified Cell-Processed Product Manufacturing License” from the Japanese Ministry of Health, Labour and Welfare, and is also accredited with the internationally recognized AABB certification. All processing is carried out under sterile conditions in a clean environment that is equivalent to GMP-level standards required for pharmaceutical manufacturing. Your child’s precious cells are carefully handled one by one by trained technical staff following global standard procedures. With reliable expertise and strict quality control, we maintain standards that allow the cells to be utilized by medical institutions both in Japan and abroad.

Video 1: “Processing Begins Within 48 Hours of Cord Blood Collection and Cord Tissue Collection! A Glimpse Inside Our Cell Processing Center”: stemcell.co.jp/wp/wp-content/themes/stemcell-renewal/video/about-cpc.mp4



Cell Storage: A 24/7, Year-Round System Watching Over Life

Our cell storage center is designed to withstand all types of disaster risks, including earthquakes and floods. Built on solid ground and located outside tsunami zones at an elevation of 12 meters, the facility’s robust structure ensures that cells are preserved long-term at ultra-low temperatures of -196°C using liquid nitrogen. Temperature is continuously monitored through a dual surveillance system, integrated with multilayer security measures such as security alarms and biometric authentication. Combining advanced technology with vigilant human oversight, we have maintained a 24/7, year-round operation with zero incidents since the facility’s establishment, safeguarding every cell entrusted to us.

Video 2: “State-of-the-Art Facility! Inside Our Cell Storage Center for Long-Term Preservation of Umbilical Cords and Cord Blood”: stemcell.co.jp/wp/wp-content/themes/stemcell-renewal/video/about-ccc.mp4




Bringing the trust we built in Japan to the future of



Southeast Asia

Since our establishment in 1999, we have been a pioneer in private cord blood banking, leading the cord blood preservation industry in Japan. Today, we hold 99% of the domestic market share, and as of the fiscal year ending March 2025, we have safely preserved over 100,000 cord tissues and cord blood samples. This milestone reflects the trust countless families have placed in us over the years.



※ Launched Cord Tissue Storage Service in the Fiscal Year Ending March 2022

Building on this foundation, we established our Singapore entity, STEMCELL INNOVATIONS PTE. LTD., in 2024. In Singapore, approximately 20% of families expecting a child preserve cord blood, and cord blood banking has become a well-established part of society as a preparation for new medical possibilities to protect the future of babies and their families. Leveraging this high awareness and demand, we formed a strategic joint venture with one of Indonesia’s largest conglomerates. Maintaining the same quality control standards for transport, processing, and storage that we developed in Japan, we are expanding our operations across Southeast Asia, centered on Singapore and Indonesia.

Through this, we provide a service that families across Asia can trust and rely on, expanding the medical potential of cord blood while contributing to the advancement of international clinical research and treatments.



Singapore Office of STEMCELL INNOVATIONS PTE. LTD

Umbilical cord blood is an irreplaceable “resource of life”. These precious cells can only be collected at the very moment a baby is born, and our mission is to connect them to the future through reliable technology and sincere management.

Building on the trust we have cultivated in Japan and the quality standards of international guidelines, our company will continue to expand this value from Japan to the world, creating a society that supports the possibilities of life.

■ StemCell Institute Inc.

With the corporate slogan “*Providing new medical care solutions for every new life*”, our company operates cell banking businesses for perinatal tissue-derived cells such as the “umbilical cord” and “cord blood,” leveraging a strong network with obstetrics and gynecology facilities. Our aim is to develop new therapies and products using these cells for regenerative and cell therapy purposes. Based on this business foundation, we strive for sustainable growth and social contribution by developing businesses and making investments in related fields such as regenerative medicine and femtech.

Established: August 5, 1999 (Listed on TSE Growth: 7096)

Capital: 704.8 million yen

President & CEO: Takafumi Shimizu

Head Office: 2F Tokyu Toranomon Building, 1-21-19 Toranomon, Minato-ku, Tokyo 105-0001

TEL / Website: 03-6811-3230 / <https://www.stemcell.co.jp/corporate/>

Group Companies: STEMCELL INNOVATIONS PTE. LTD. (Singapore), Milcare Co., Ltd.

【For media inquiries regarding this announcement】

StemCell Institute Inc. Corporate Planning Division, Miho Isomura

TEL : 03-6811-3235 / MAIL : pr@stemcell.co.jp